Recent clinical data underscore the growing role of amivantamab, a bsAb targeting both EGFR and MET, in the treatment of NSCLC, particularly among patients with EGFR mutations and MET alterations [183]. This evidence concerns the gene MET and non-small cell lung carcinoma.